247 related articles for article (PubMed ID: 21996947)
1. [Hypoxic microenvironment and cancer dormancy].
Okuyama H; Inoue M
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1559-64. PubMed ID: 21996947
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
Tomida A; Tsuruo T
Anticancer Drug Des; 1999 Apr; 14(2):169-77. PubMed ID: 10405643
[TBL] [Abstract][Full Text] [Related]
3. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
4. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs.
Onozuka H; Tsuchihara K; Esumi H
Cancer Sci; 2011 May; 102(5):975-82. PubMed ID: 21255190
[TBL] [Abstract][Full Text] [Related]
6. Cancer dormancy: a model of early dissemination and late cancer recurrence.
Páez D; Labonte MJ; Bohanes P; Zhang W; Benhanim L; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
Clin Cancer Res; 2012 Feb; 18(3):645-53. PubMed ID: 22156560
[TBL] [Abstract][Full Text] [Related]
7. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia.
Cao X; Fang L; Gibbs S; Huang Y; Dai Z; Wen P; Zheng X; Sadee W; Sun D
Cancer Chemother Pharmacol; 2007 Mar; 59(4):495-505. PubMed ID: 16906425
[TBL] [Abstract][Full Text] [Related]
8. pH control mechanisms of tumor survival and growth.
Parks SK; Chiche J; Pouyssegur J
J Cell Physiol; 2011 Feb; 226(2):299-308. PubMed ID: 20857482
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic cells in tumors as a target for cancer therapy.
Gali-Muhtasib HU; Diab-Assef M; Haddadin MJ
J Med Liban; 2002; 50(4):175-9. PubMed ID: 15298478
[TBL] [Abstract][Full Text] [Related]
10. Tumor Dormancy and Interplay with Hypoxic Tumor Microenvironment.
Butturini E; Carcereri de Prati A; Boriero D; Mariotto S
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484342
[TBL] [Abstract][Full Text] [Related]
11. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
[TBL] [Abstract][Full Text] [Related]
12. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies.
Magagnin MG; Koritzinsky M; Wouters BG
Drug Resist Updat; 2006; 9(4-5):185-97. PubMed ID: 16926105
[TBL] [Abstract][Full Text] [Related]
13. The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers.
Anderson KM; Tsui P; Guinan P; Rubenstein M
Anticancer Res; 2006; 26(6B):4155-62. PubMed ID: 17201127
[TBL] [Abstract][Full Text] [Related]
14. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material.
Lotfi R; Eisenbacher J; Solgi G; Fuchs K; Yildiz T; Nienhaus C; Rojewski MT; Schrezenmeier H
Eur J Immunol; 2011 Jul; 41(7):2021-8. PubMed ID: 21538978
[TBL] [Abstract][Full Text] [Related]
15. Effects of hypoxia on tumor metabolism.
Kim JW; Gao P; Dang CV
Cancer Metastasis Rev; 2007 Jun; 26(2):291-8. PubMed ID: 17415528
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.
Dang DT; Chen F; Gardner LB; Cummins JM; Rago C; Bunz F; Kantsevoy SV; Dang LH
Cancer Res; 2006 Feb; 66(3):1684-936. PubMed ID: 16452228
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia in cancer malignity. Review].
Arvelo F; Cotte C
Invest Clin; 2009 Dec; 50(4):529-46. PubMed ID: 20306726
[TBL] [Abstract][Full Text] [Related]
18. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
Kardosh A; Soriano N; Pyrko P; Liu YT; Jabbour M; Hofman FM; Schönthal AH
J Biomed Sci; 2007 Sep; 14(5):647-62. PubMed ID: 17440835
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cell death in the tumor microenvironment.
Wouters BG; Koritzinsky M; Chiu RK; Theys J; Buijsen J; Lambin P
Semin Radiat Oncol; 2003 Jan; 13(1):31-41. PubMed ID: 12520462
[TBL] [Abstract][Full Text] [Related]
20. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
